We are live on ! Find out more
AG

Artal Group Portfolio holdings

AUM $1.01B
1-Year Est. Return 29.84%
This Fund
S&P 500
This Quarter Est. Return
+41.14%
1 Year Est. Return
+29.84%
3 Year Est. Return
+144%
5 Year Est. Return
+76.57%
10 Year Est. Return
+1,417.6%
AUM
$4.71B
AUM Growth
-$3.29B
Cap. Flow
-$4.28B
Cap. Flow %
-91.04%
Top 10 Hldgs %
76.49%
Holding
126
New
17
Increased
33
Reduced
15
Closed
22

Top Buys

Rank Stock Value
1
SRRK icon
Scholar Rock
SRRK
+$44.9M
2
LXRX icon
Lexicon Pharmaceuticals
LXRX
+$20.1M
3
BPMC
Blueprint Medicines
BPMC
+$19.9M
4
NKTR icon
Nektar Therapeutics
NKTR
+$15.4M
5
AUTL
Autolus Therapeutics
AUTL
+$13.9M

Top Sells

Rank Stock Value
1
BUFF
Blue Buffalo Pet Products, Inc
BUFF
+$3.48B
2
WW
WW International
WW
+$678M
3
INCY icon
Incyte
INCY
+$25M
4
AVXS
AveXis, Inc. Common Stock
AVXS
+$19.8M
5
AGIO icon
Agios Pharmaceuticals
AGIO
+$13.1M

Sector Composition

Rank Sector Weight
1 Consumer Discretionary 44.73%
2 Healthcare 36.09%
3 Communication Services 0%
4 Consumer Staples 0%
5 Materials 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
WW
1
DELISTED
WW International
WW
$2.1B 44.73%
20,818,300
-8,625,000
-29% -$678M
LXRX icon
2
Lexicon Pharmaceuticals
LXRX
$1.04B
$723M 15.36%
60,240,864
+1,966,214
+3% +$20.1M
BAC icon
3
CALL
Bank of America
BAC
$439B
$179M 3.8%
6,350,000
+2,000,000
+46% +$59.7M
CELG
4
CALL
DELISTED
Celgene Corp
CELG
$159M 3.38%
2,000,000
+1,350,000
+208% +$112M
ONC
5
BeOne Medicines Ltd
ONC
$34.3B
$104M 2.21%
675,000
+75,000
+13% +$13.4M
MS icon
6
CALL
Morgan Stanley
MS
$333B
$71.1M 1.51%
+1,500,000
New +$78.4M
BMY icon
7
CALL
Bristol-Myers Squibb
BMY
$130B
$69.2M 1.47%
1,250,000
+350,000
+39% +$18.9M
GS icon
8
CALL
Goldman Sachs
GS
$305B
$66.2M 1.41%
300,000
-50,000
-14% -$11.9M
ALNY icon
9
Alnylam Pharmaceuticals
ALNY
$38.5B
$64M 1.36%
650,000
+50,000
+8% +$4.96M
GM icon
10
CALL
General Motors
GM
$81.7B
$59.1M 1.26%
1,500,000
-2,000,000
-57% -$78.7M
WFC icon
11
CALL
Wells Fargo
WFC
$263B
$55.4M 1.18%
1,000,000
-300,000
-23% -$16.1M
IBB icon
12
CALL
iShares Biotechnology ETF
IBB
$9.55B
$49.4M 1.05%
+450,000
New +$48.1M
XLRN
13
DELISTED
Acceleron Pharma
XLRN
$48.5M 1.03%
1,000,000
+150,000
+18% +$5.47M
FOLD
14
DELISTED
Amicus Therapeutics
FOLD
$45.3M 0.96%
2,900,000
+400,000
+16% +$6.05M
BPMC
15
DELISTED
Blueprint Medicines
BPMC
$44.4M 0.94%
700,000
+250,000
+56% +$19.9M
NKTR icon
16
Nektar Therapeutics
NKTR
$2.39B
$43.9M 0.93%
60,000
+13,333
+29% +$15.4M
SRRK icon
17
Scholar Rock
SRRK
$5.92B
$37.4M 0.79%
+2,396,040
New +$44.9M
ATRA icon
18
Atara Biotherapeutics
ATRA
$70.4M
$36.8M 0.78%
40,000
-10,000
-20% -$10.7M
TSRO
19
DELISTED
TESARO, Inc.
TSRO
$35.6M 0.76%
800,000
+200,000
+33% +$9.71M
ARRY
20
DELISTED
Array Biopharma Inc
ARRY
$33.6M 0.71%
2,000,000
– –
AGIO icon
21
Agios Pharmaceuticals
AGIO
$2.14B
$29.5M 0.63%
350,000
-150,000
-30% -$13.1M
BLUE
22
DELISTED
bluebird bio
BLUE
$26.7M 0.57%
13,124
+1,544
+13% +$3.52M
MDCO
23
CALL
DELISTED
Medicines Co
MDCO
$25.7M 0.55%
700,000
– –
ZGNX
24
DELISTED
Zogenix, Inc.
ZGNX
$22.1M 0.47%
500,000
+300,000
+150% +$12.4M
FATE icon
25
Fate Therapeutics
FATE
$270M
$19.3M 0.41%
1,700,000
+850,000
+100% +$9.36M
1
2 3 4 5

Similar funds

BCM
Bronte Capital Management Bondi Junction, Australia $1.01B AUM 47.99% 1-Year Est. Return
GA
GRS Advisors Chicago, Illinois $1.01B AUM 13.12% 1-Year Est. Return
EPAM
Euro Pacific Asset Management Dorado, Puerto Rico $1.01B AUM 79.26% 1-Year Est. Return
WA
Wealth Alliance Mellville, New York $1.01B AUM 19.71% 1-Year Est. Return
CT
Coastline Trust Providence, Rhode Island $1.01B AUM 22.57% 1-Year Est. Return
AH
Allen Holding New York $1.01B AUM 27.61% 1-Year Est. Return
PIM
Provident Investment Management Novi, Michigan $1.01B AUM 9.4% 1-Year Est. Return
MAM
Melqart Asset Management London, United Kingdom $1.01B AUM 84.85% 1-Year Est. Return

Artal Group's Q2 2018 Portfolio in Review

As of Q2 2018, Artal Group held 126 positions worth $4.71B, down 41% from $7.99B the previous quarter. Its ten largest holdings account for 76% of the portfolio.

Artal Group withdrew a net $4.28B in Q2 2018, closing 22 positions and reducing 15 holdings. Its most notable exit was Blue Buffalo Pet Products, Inc, an estimated $3.48B position sold in full.

By sector, the portfolio is most concentrated in Consumer Discretionary at 45% of assets, up from 23% a quarter earlier, followed by Healthcare and Communication Services.

Against the trend, Artal Group opened a new position in Scholar Rock worth $37.4M.

  • Artal Group's largest Q2 2018 buy was Scholar Rock: 2,396,040 shares worth $37.4M.
  • Artal Group added most to Lexicon Pharmaceuticals in Q2 2018, an estimated $20.1M increase.
  • Artal Group's biggest Q2 2018 reduction was WW International, cutting an estimated $678M.
  • Artal Group fully exited Blue Buffalo Pet Products, Inc in Q2 2018, selling an estimated $3.48B.
  • Artal Group's ten largest holdings make up 76% of its $4.71B portfolio in Q2 2018.
  • Artal Group opened 17 new positions and closed 22 in Q2 2018.
  • Artal Group's portfolio value fell 41% quarter-over-quarter to $4.71B.

Based on Artal Group's 13F filing for Q2 2018, filed 10 Aug 2018.